SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

This syndrome plays a significant role in elevating the risk of developing cardiovascular diseases, which encompass serious ...

In the complex landscape of reproductive health, emergency contraception stands as a critical option for individuals seeking ...

Turmeric is touted as a cure-all spice but nutrition experts are more cautious about recommending turmeric for everything.

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...

Myasthenia gravis treatment aims to minimize the effects of muscle weakness due to an immune process. It includes medications ...

The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.

Nattawat Klomjit, MD, shares insights on managing IgA nephropathy and C3 glomerulopathy, including innovative drugs that target kidney inflammation and proteinuria.

A recent study conducted in Sweden found that GLP-1 agonists such as Ozempic and Wegovy may help reduce alcohol consumption and related harms in individuals diagnosed with alcohol use disorder. Here ...

Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it has formed a nonexclusive agreement with Ques ...